- Home
- CRDF vs CATX Comparison
CRDF vs CATX Comparison
Compare CRDF & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- CATX
- Stock Information
- Founded
- CRDF 1999
- CATX 1983
- Country
- CRDF United States
- CATX United States
- Employees
- CRDF N/A
- CATX N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- CATX Medical/Dental Instruments
- Sector
- CRDF Health Care
- CATX Health Care
- Exchange
- CRDF Nasdaq
- CATX Nasdaq
- Market Cap
- CRDF 233.5M
- CATX 239.0M
- IPO Year
- CRDF N/A
- CATX N/A
- Fundamental
- Price
- CRDF $2.64
- CATX $3.67
- Analyst Decision
- CRDF Strong Buy
- CATX Strong Buy
- Analyst Count
- CRDF 6
- CATX 11
- Target Price
- CRDF $11.92
- CATX $12.90
- AVG Volume (30 Days)
- CRDF 3.0M
- CATX 963.3K
- Earning Date
- CRDF 07-29-2025
- CATX 08-13-2025
- Dividend Yield
- CRDF N/A
- CATX N/A
- EPS Growth
- CRDF N/A
- CATX N/A
- EPS
- CRDF N/A
- CATX N/A
- Revenue
- CRDF $545,000.00
- CATX $1,471,000.00
- Revenue This Year
- CRDF N/A
- CATX N/A
- Revenue Next Year
- CRDF N/A
- CATX $11.99
- P/E Ratio
- CRDF N/A
- CATX N/A
- Revenue Growth
- CRDF N/A
- CATX N/A
- 52 Week Low
- CRDF $2.01
- CATX $1.60
- 52 Week High
- CRDF $5.64
- CATX $16.55
- Technical
- Relative Strength Index (RSI)
- CRDF 34.68
- CATX 44.88
- Support Level
- CRDF $2.31
- CATX $3.88
- Resistance Level
- CRDF $4.52
- CATX $4.28
- Average True Range (ATR)
- CRDF 0.37
- CATX 0.27
- MACD
- CRDF -0.21
- CATX -0.08
- Stochastic Oscillator
- CRDF 14.67
- CATX 2.32
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.